Science Advances · 2023 · 22 citations · 49 references
MedicineMolecular BiologyOncologyCancer GeneticsEpigeneticsMolecular OncologyCancer Cell SignalingCancer EpigeneticsEpigenetic Alterations In CancerEpigenetic Regulation In CancerOncogenic Signaling PathwaysSignal Transduction In CancerCancer Signaling PathwaysCell Growth RegulationEpigenetic ControlEpigenetic Enzyme MechanismsEpigenetic TherapiesGain-of-function VariantsMolecular Drug ResistanceRaf-mek-erk Signaling
Lung cancer is a lethal malignancy lacking effective therapies. Emerging evidence suggests that epigenetic enzyme mutations are closely related to the malignant phenotype of lung cancer. Here, we identified a series of gain-of-function mutations in the histone methyltransferase DOT1L. The strongest of them is R231Q, located in the catalytic DOT domain. R231Q can enhance the substrate binding ability of DOT1L. Moreover, R231Q promotes cell growth and drug resistance of lung cancer cells in vitro and in vivo. Mechanistic studies also revealed that the R231Q mutant specifically activates the MAPK/ERK signaling pathway by enriching H3K79me2 on the RAF1 promoter and epigenetically regulating the expression of downstream targets. The combination of a DOT1L inhibitor (SGC0946) and a MAPK/ERK axis inhibitor (binimetinib) can effectively reverse the R231Q-induced phenomena. Our results reveal gain-of-function mutations in an epigenetic enzyme and provide promising insights for the precise treatment of lung cancer patients.
49
Ethan Cerami, Jianjiong Gao, Uğur Doğrusöz et al. · Cancer Discovery · 2012 · 18.4K citations · Full text
Medicine, Bioinformatics, Oncology +15
Rebecca L. Siegel, Kimberly D. Miller, Hannah E. Fuchs et al. · CA A Cancer Journal for Clinicians · 2022 · 18.2K citations · Full text
CASTp 3.0: computed atlas of surface topography of proteins
Wei Tian, Chang Chen, Xue Lei et al. · Nucleic Acids Research · 2018 · 2.4K citations · Full text